CH675831A5 - - Google Patents

Download PDF

Info

Publication number: CH675831A5
Authority: CH; Switzerland
Prior art keywords: asa; hours; dose; day; composition according
Prior art date: 1986-10-09

Application number

CH3838/87A

Other languages

German (de)

English (en)

Inventor

Henry C Gan

Original Assignee

Sandoz Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1986-10-09

Filing date

1987-10-02

Publication date

1990-11-15

1987-10-02 Application filed by Sandoz Ag filed Critical Sandoz Ag

1990-11-15 Publication of CH675831A5 publication Critical patent/CH675831A5/de

Links

BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims description 51
239000000203 mixture Substances 0.000 claims description 36
229920000168 Microcrystalline cellulose Polymers 0.000 claims description 16
239000008108 microcrystalline cellulose Substances 0.000 claims description 16
235000019813 microcrystalline cellulose Nutrition 0.000 claims description 16
229940016286 microcrystalline cellulose Drugs 0.000 claims description 16
239000008194 pharmaceutical composition Substances 0.000 claims description 16
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 14
229960001138 acetylsalicylic acid Drugs 0.000 claims description 12
238000000034 method Methods 0.000 claims description 12
239000002831 pharmacologic agent Substances 0.000 claims description 6
238000006116 polymerization reaction Methods 0.000 claims description 3
239000002552 dosage form Substances 0.000 claims description 2
125000005273 2-acetoxybenzoic acid group Chemical group 0.000 claims 2
YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 36
FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 18
229960004889 salicylic acid Drugs 0.000 description 18
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 10
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 10
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 10
229920000881 Modified starch Polymers 0.000 description 9
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 9
229960001860 salicylate Drugs 0.000 description 9
YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 9
239000004480 active ingredient Substances 0.000 description 8
239000012729 immediate-release (IR) formulation Substances 0.000 description 8
-1 neuroleptics Substances 0.000 description 6
210000004369 blood Anatomy 0.000 description 5
239000008280 blood Substances 0.000 description 5
210000002381 plasma Anatomy 0.000 description 5
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
229920000856 Amylose Polymers 0.000 description 4
235000021355 Stearic acid Nutrition 0.000 description 4
239000013543 active substance Substances 0.000 description 4
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 4
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 4
239000002245 particle Substances 0.000 description 4
230000036470 plasma concentration Effects 0.000 description 4
239000008117 stearic acid Substances 0.000 description 4
210000002700 urine Anatomy 0.000 description 4
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
229920000945 Amylopectin Polymers 0.000 description 3
229920002261 Corn starch Polymers 0.000 description 3
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
229920002472 Starch Polymers 0.000 description 3
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
230000003110 anti-inflammatory effect Effects 0.000 description 3
230000001186 cumulative effect Effects 0.000 description 3
230000003111 delayed effect Effects 0.000 description 3
238000002474 experimental method Methods 0.000 description 3
238000009472 formulation Methods 0.000 description 3
238000004128 high performance liquid chromatography Methods 0.000 description 3
239000000463 material Substances 0.000 description 3
239000000377 silicon dioxide Substances 0.000 description 3
235000012239 silicon dioxide Nutrition 0.000 description 3
239000007787 solid Substances 0.000 description 3
239000008107 starch Substances 0.000 description 3
235000019698 starch Nutrition 0.000 description 3
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
208000002193 Pain Diseases 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
239000004743 Polypropylene Substances 0.000 description 2
229910000831 Steel Inorganic materials 0.000 description 2
230000001754 anti-pyretic effect Effects 0.000 description 2
239000002221 antipyretic Substances 0.000 description 2
230000002490 cerebral effect Effects 0.000 description 2
239000008119 colloidal silica Substances 0.000 description 2
230000000052 comparative effect Effects 0.000 description 2
239000008120 corn starch Substances 0.000 description 2
239000013078 crystal Substances 0.000 description 2
230000000694 effects Effects 0.000 description 2
230000008030 elimination Effects 0.000 description 2
238000003379 elimination reaction Methods 0.000 description 2
230000029142 excretion Effects 0.000 description 2
239000008187 granular material Substances 0.000 description 2
229940031702 hydroxypropyl methylcellulose 2208 Drugs 0.000 description 2
238000011835 investigation Methods 0.000 description 2
230000000302 ischemic effect Effects 0.000 description 2
239000000314 lubricant Substances 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
230000004060 metabolic process Effects 0.000 description 2
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
229920001155 polypropylene Polymers 0.000 description 2
102000004169 proteins and genes Human genes 0.000 description 2
108090000623 proteins and genes Proteins 0.000 description 2
239000010959 steel Substances 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
FODBVCSYJKNBLO-UHFFFAOYSA-N 2,3-dimethoxybenzoic acid Chemical compound COC1=CC=CC(C(O)=O)=C1OC FODBVCSYJKNBLO-UHFFFAOYSA-N 0.000 description 1
229920003084 Avicel® PH-102 Polymers 0.000 description 1
208000008035 Back Pain Diseases 0.000 description 1
206010006811 Bursitis Diseases 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
208000008930 Low Back Pain Diseases 0.000 description 1
235000019759 Maize starch Nutrition 0.000 description 1
229920003091 Methocel™ Polymers 0.000 description 1
206010029240 Neuritis Diseases 0.000 description 1
206010037660 Pyrexia Diseases 0.000 description 1
208000008765 Sciatica Diseases 0.000 description 1
239000002253 acid Substances 0.000 description 1
238000010306 acid treatment Methods 0.000 description 1
239000000654 additive Substances 0.000 description 1
239000000853 adhesive Substances 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
230000000202 analgesic effect Effects 0.000 description 1
229940035676 analgesics Drugs 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
239000000730 antalgic agent Substances 0.000 description 1
230000000181 anti-adherent effect Effects 0.000 description 1
230000001088 anti-asthma Effects 0.000 description 1
229940124599 anti-inflammatory drug Drugs 0.000 description 1
239000000924 antiasthmatic agent Substances 0.000 description 1
229940125681 anticonvulsant agent Drugs 0.000 description 1
239000001961 anticonvulsive agent Substances 0.000 description 1
239000000935 antidepressant agent Substances 0.000 description 1
229940005513 antidepressants Drugs 0.000 description 1
239000003831 antifriction material Substances 0.000 description 1
229940125715 antihistaminic agent Drugs 0.000 description 1
239000000739 antihistaminic agent Substances 0.000 description 1
239000002220 antihypertensive agent Substances 0.000 description 1
229940030600 antihypertensive agent Drugs 0.000 description 1
229940125716 antipyretic agent Drugs 0.000 description 1
206010003246 arthritis Diseases 0.000 description 1
229940058671 bayer aspirin Drugs 0.000 description 1
230000036765 blood level Effects 0.000 description 1
230000037058 blood plasma level Effects 0.000 description 1
230000037396 body weight Effects 0.000 description 1
159000000007 calcium salts Chemical class 0.000 description 1
238000004364 calculation method Methods 0.000 description 1
235000010980 cellulose Nutrition 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229940075614 colloidal silicon dioxide Drugs 0.000 description 1
239000003086 colorant Substances 0.000 description 1
239000000470 constituent Substances 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000003814 drug Substances 0.000 description 1
239000000284 extract Substances 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
239000008103 glucose Substances 0.000 description 1
150000004676 glycans Chemical class 0.000 description 1
229910052739 hydrogen Inorganic materials 0.000 description 1
239000001257 hydrogen Substances 0.000 description 1
230000002757 inflammatory effect Effects 0.000 description 1
239000008101 lactose Substances 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
YLGXILFCIXHCMC-JHGZEJCSSA-N methyl cellulose Chemical compound COC1C(OC)C(OC)C(COC)O[C@H]1O[C@H]1C(OC)C(OC)C(OC)OC1COC YLGXILFCIXHCMC-JHGZEJCSSA-N 0.000 description 1
208000004296 neuralgia Diseases 0.000 description 1
229920001282 polysaccharide Polymers 0.000 description 1
239000005017 polysaccharide Substances 0.000 description 1
201000003068 rheumatic fever Diseases 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
238000010972 statistical evaluation Methods 0.000 description 1
239000000126 substance Substances 0.000 description 1
230000008961 swelling Effects 0.000 description 1
210000002105 tongue Anatomy 0.000 description 1
239000003204 tranquilizing agent Substances 0.000 description 1
230000002936 tranquilizing effect Effects 0.000 description 1
238000000870 ultraviolet spectroscopy Methods 0.000 description 1
230000036325 urinary excretion Effects 0.000 description 1
239000005526 vasoconstrictor agent Substances 0.000 description 1
229940124549 vasodilator Drugs 0.000 description 1
239000003071 vasodilator agent Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)

CH3838/87A 1986-10-09 1987-10-02 CH675831A5 (fr)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GB868624213A GB8624213D0 (en)	1986-10-09	1986-10-09	Sustained release pharmaceutical compositions

Publications (1)

Publication Number	Publication Date
CH675831A5 true CH675831A5 (fr)	1990-11-15

Family

ID=10605478

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CH3838/87A CH675831A5 (fr)	1986-10-09	1987-10-02

Country Status (24)

Country	Link
JP (1)	JPS63101334A (fr)
KR (1)	KR880004801A (fr)
AU (1)	AU7942087A (fr)
BE (1)	BE1000732A5 (fr)
CA (1)	CA1332809C (fr)
CH (1)	CH675831A5 (fr)
DE (1)	DE3733540A1 (fr)
DK (1)	DK527487A (fr)
ES (1)	ES2014518A6 (fr)
FI (1)	FI874414L (fr)
FR (1)	FR2604902B1 (fr)
GB (2)	GB8624213D0 (fr)
GR (1)	GR871550B (fr)
HU (1)	HU201875B (fr)
IL (1)	IL84104A0 (fr)
IT (1)	IT1221493B (fr)
LU (1)	LU87009A1 (fr)
NL (1)	NL8702294A (fr)
NO (1)	NO874200L (fr)
NZ (1)	NZ222083A (fr)
PH (1)	PH24227A (fr)
PT (1)	PT85880B (fr)
SE (1)	SE8703889L (fr)
ZA (1)	ZA877617B (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5948437A (en) *	1996-05-23	1999-09-07	Zeneca Limited	Pharmaceutical compositions using thiazepine
US5895663A (en) *	1997-07-31	1999-04-20	L. Perrigo Company	Pseudoephedrine hydrochloride extended-release tablets
MX339071B (es) *	1999-03-31	2016-05-09	Janssen Pharmaceutica Nv	Almidon pregelatinizado en una formulacion de liberacion controlada.
US6242003B1 (en)	2000-04-13	2001-06-05	Novartis Ag	Organic compounds
US20060127474A1 (en)	2001-04-11	2006-06-15	Oskar Kalb	Pharmaceutical compositions comprising fluvastatin
SE0102887D0 (sv) *	2001-08-29	2001-08-29	Astrazeneca Ab	New formulation
SE0102886D0 (sv) *	2001-08-29	2001-08-29	Astrazeneca Ab	New formulation
SE0102888D0 (sv) *	2001-08-29	2001-08-29	Astrazeneca Ab	New formulation
TWI338583B (en)	2004-05-20	2011-03-11	Otsuka Pharma Co Ltd	Solid pharmaceutical formulation
US7820200B2 (en) *	2004-09-09	2010-10-26	Luis Estrada Flores	Pharmaceutical composition for the sustained release of hydralazine and use thereof as a support for cancer treatment

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
BE795766A (fr) *	1972-02-22	1973-08-22	Lilly Co Eli	Particules de napsylate de propoxyphene retard et procede de fabrication de ces particules
US4389393A (en) *	1982-03-26	1983-06-21	Forest Laboratories, Inc.	Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose
US4520009A (en) *	1983-11-28	1985-05-28	Verex Laboratories, Inc.	Sustained released aspirin formulation
DE3346571A1 (de) *	1983-12-23	1985-07-04	Bayer Ag, 5090 Leverkusen	Oral retardierte acetylsalicylsaeureformulierungen
JPS61501511A (ja) *	1984-03-21	1986-07-24	アメリカン・ホ−ム・プロダクツ・コ−ポレイション	徐放性医薬カプセル

1986
- 1986-10-09 GB GB868624213A patent/GB8624213D0/en active Pending
1987
- 1987-09-25 NL NL8702294A patent/NL8702294A/nl not_active Application Discontinuation
- 1987-09-25 HU HU874311A patent/HU201875B/hu not_active IP Right Cessation
- 1987-10-02 FR FR878713759A patent/FR2604902B1/fr not_active Expired - Lifetime
- 1987-10-02 CH CH3838/87A patent/CH675831A5/de not_active IP Right Cessation
- 1987-10-02 BE BE8701131A patent/BE1000732A5/fr not_active IP Right Cessation
- 1987-10-03 DE DE19873733540 patent/DE3733540A1/de not_active Withdrawn
- 1987-10-06 LU LU87009A patent/LU87009A1/fr unknown
- 1987-10-06 KR KR870011168A patent/KR880004801A/ko not_active Withdrawn
- 1987-10-06 IL IL84104A patent/IL84104A0/xx unknown
- 1987-10-07 GB GB8723515A patent/GB2195893B/en not_active Expired - Lifetime
- 1987-10-07 NO NO874200A patent/NO874200L/no unknown
- 1987-10-07 NZ NZ222083A patent/NZ222083A/en unknown
- 1987-10-07 GR GR871550A patent/GR871550B/el unknown
- 1987-10-07 FI FI874414A patent/FI874414L/fi not_active IP Right Cessation
- 1987-10-07 PT PT85880A patent/PT85880B/pt not_active IP Right Cessation
- 1987-10-07 AU AU79420/87A patent/AU7942087A/en not_active Abandoned
- 1987-10-08 JP JP62256149A patent/JPS63101334A/ja active Pending
- 1987-10-08 ES ES8702873A patent/ES2014518A6/es not_active Expired - Lifetime
- 1987-10-08 CA CA000548872A patent/CA1332809C/fr not_active Expired - Lifetime
- 1987-10-08 SE SE8703889A patent/SE8703889L/ not_active Application Discontinuation
- 1987-10-08 DK DK527487A patent/DK527487A/da not_active Application Discontinuation
- 1987-10-08 PH PH35906A patent/PH24227A/en unknown
- 1987-10-08 IT IT48469/87A patent/IT1221493B/it active
- 1987-10-09 ZA ZA877617A patent/ZA877617B/xx unknown

Also Published As

Publication number	Publication date
FR2604902A1 (fr)	1988-04-15
NZ222083A (en)	1991-05-28
FI874414A7 (fi)	1988-04-10
ZA877617B (en)	1989-05-30
DK527487A (da)	1988-04-10
PT85880B (pt)	1990-07-31
BE1000732A5 (fr)	1989-03-21
NO874200L (no)	1988-04-11
SE8703889L (sv)	1988-04-10
IL84104A0 (en)	1988-03-31
GB2195893B (en)	1991-05-08
IT1221493B (it)	1990-07-06
KR880004801A (ko)	1988-06-27
GR871550B (en)	1988-02-15
JPS63101334A (ja)	1988-05-06
PH24227A (en)	1990-05-04
FI874414A0 (fi)	1987-10-07
FI874414L (fi)	1988-04-10
GB2195893A (en)	1988-04-20
LU87009A1 (fr)	1988-05-03
ES2014518A6 (es)	1990-07-16
FR2604902B1 (fr)	1991-04-26
GB8624213D0 (en)	1986-11-12
HU201875B (en)	1991-01-28
SE8703889D0 (sv)	1987-10-08
DK527487D0 (da)	1987-10-08
AU7942087A (en)	1988-04-14
NO874200D0 (no)	1987-10-07
DE3733540A1 (de)	1988-04-14
PT85880A (en)	1987-11-01
HUT52958A (en)	1990-09-28
GB8723515D0 (en)	1987-11-11
IT8748469A0 (it)	1987-10-08
NL8702294A (nl)	1988-05-02
CA1332809C (fr)	1994-11-01

Legal Events

Date	Code	Title	Description
1996-04-15	SPCF	Supplementary protection certificate filed	Free format text: IKS 51189/940223
1996-06-14	SPCF	Supplementary protection certificate filed	Free format text: IKS 52189/940223, 951214
1996-10-31	SPCR	Supplementary protection certificate rejected	Free format text: IKS 51189/940223, 951214
1997-05-15	PFA	Name/firm changed	Owner name: SANDOZ AG TRANSFER- NOVARTIS AG
2007-10-30	PL	Patent ceased

Publication	Publication Date	Title
DE69004708T2 (de)	1994-03-24	Tablette mit Doppelwirkung.
DE69400215T2 (de)	1996-10-31	Tramadol enthaltendes Arzneimittel mit verzögerter Wirkstoffabgabe
DE69730314T2 (de)	2005-08-18	Dosierungsform von ibuprofen
DE69826290T2 (de)	2005-02-17	Pharmazeutische zusammensetzungen zur kontrollierten freigabe von wirkstoffen
DE69533492T2 (de)	2005-01-27	Orale Metoprolol-Dosisform des Typs "einmal täglich"
DE69802543T2 (de)	2002-08-22	Verbesserte multipartikel-tablette mit schnellauflösbarkeit
DE19541128C2 (de)	1997-11-27	Stabilisierte schilddrüsenhormonhaltige Arzneimittel
DE69623634T2 (de)	2003-05-22	Pharmazeutische zusammensetzung von l-dopa ethyl ester
EP2477660B1 (fr)	2015-02-11	Composition pharmaceutique renfermant les agents actifs metformine et sitagliptine ou vildagliptine
DE69209080T2 (de)	1996-08-01	Pharmazeutische zusammemsetzungen mit verzoegerter freigabe
DE69924987T2 (de)	2006-06-08	Pharmazeutische Zusammensetzung enthaltend synthetisch natürliches Progesteron und Östradiol und Verfahren zur Herstellung derselben
DE69814850T2 (de)	2004-03-11	Paracetamol enthaltende schlickbare tablette
DE69518237T2 (de)	2001-02-22	Feste pharmazeutische zubereitung mit (s)-2-(4-isobutylphenyl)propionsäure als wirkstoff und mikrokristalliner cellulose und kolloidalem silica als hilfstoff
LU84962A1 (de)	1983-12-28	Naproxen-und naproxen-natrium-tabletten mit kontrollierter wirkstoffreigabe
EP0250648A2 (fr)	1988-01-07	Préparation pharmaceutique pour la libération retardée de l'ibuprofène
DE10003757A1 (de)	2001-08-02	Ibuprofen-Wirkstoffzubereitung
DE60225686T2 (de)	2009-04-16	Paracetamol enthaltende tablette
DE2128461A1 (de)	1971-12-16	Pharmazeutisches Präparat
DE3733540A1 (de)	1988-04-14	Eine pharmazeutische zusammensetzung mit verzoegerter freigabe des wirkstoffes
DE60309565T2 (de)	2007-03-15	Tablettenzubereitung mit verlängerter Freisetzung von Venlafaxin
EP2515852B1 (fr)	2016-03-02	Comprimé orodispersible contenant une base de sildenafil compactée
DE60320039T2 (de)	2009-05-14	Tramadol-formulierungen mit verzögerter freisetzung und 24-stunden-wirksamkeit
DE69428455T3 (de)	2005-01-20	Verfahren zur herstellung von niedrigdosierten arzneimitteln
DE69626676T2 (de)	2003-12-18	Schnell freisetzende tablette enthaltend tolfenaminsäure oder ein pharmazeutisch verträgliches salz davon
DE3226178A1 (de)	1983-01-20	Mittel enthaltend n-acetyl-p-aminophenol und ein antacidum